Allurion Technologies Inc. (NYSE:ALUR) Q1 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights a mixed picture. While there are positive developments like reduced operating expenses, restructuring benefits, and FDA approval progress, uncertainties remain. The Q&A reveals cautious optimism about regional growth and trial prospects but lacks concrete timelines for France's recovery. The absence of material Virtual Care Suite revenues soon adds to uncertainty. Despite positive restructuring impacts, the lack of immediate revenue growth and specific guidance tempers optimism, suggesting a neutral sentiment.
Key Financial Performance
Revenue $5.6 million (decrease of 40% year-over-year from $9.4 million); primarily due to the temporary suspension of sales in France and lower investments in sales and marketing.
Gross Profit $4.2 million (75% of revenue, increase from 73% year-over-year); driven by increased manufacturing efficiencies resulting from restructuring initiatives.
Sales and Marketing Expenses $3.6 million (decrease of 41% year-over-year from $6.1 million); reduction driven by increased operating efficiency and restructuring initiatives.
Research and Development Expenses $2.6 million (decrease of 54% year-over-year from $5.7 million); reduction primarily due to decreased costs related to the AUDACITY trial and restructuring initiatives.
General and Administrative Expenses $5.2 million (decrease of 19% year-over-year from $6.4 million); adjusted expenses were $3.8 million excluding one-time financing costs of $1.4 million, driven by restructuring initiatives.
Loss from Operations $7.3 million (decrease of 36% year-over-year from $11.4 million); reduction driven by restructuring initiatives and expansion in gross margin.
Adjusted Loss from Operations $5.9 million (excluding one-time financing costs of $1.4 million); reduction driven by restructuring initiatives and expansion in gross margin.
Cash and Cash Equivalents $20.4 million as of March 31, 2025; provides runway for achieving FDA approval and profitability.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
New Product Launch: We are building out AllurionMeds to offer brand name GLP-1s, which could be an attractive option for U.S. patients, especially at lower doses in combination with the Allurion Balloon.
Clinical Trials: We intend to launch a prospective trial combining the Allurion Balloon with low-dose semaglutide, which could become a new standard-of-care for obesity.
Market Expansion: We are resuming commercialization in France, re-engaging clinics and retraining providers.
New Commercial Plan: We are implementing a B2B2C direct sales model, which has shown over 40% growth quarter-over-quarter and year-over-year.
Operational Efficiency: Adjusted operating expenses decreased by 45% compared to the prior year, and gross margin expanded to 75%.
Cash Position: As of March 31, 2025, we had cash and cash equivalents of $20 million, providing a runway for achieving FDA approval and profitability.
Strategic Shift: We are shifting to a B2B2C model from a direct-to-consumer model, focusing on key geographies for deeper penetration.
FDA Approval Path: We completed our pre-PMA meeting with the FDA and expect to submit our PMA application by the end of June.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Risks: The company is working towards FDA approval for the Allurion Balloon and has recently completed a pre-PMA meeting with the FDA. There is uncertainty regarding the approval process and the need for additional analyses to address control group performance.
Market Risks: The revenue for Q1 2025 decreased to $5.6 million from $9.4 million in Q1 2024, primarily due to the temporary suspension of sales in France and lower investments in sales and marketing.
Operational Risks: The company has undergone restructuring initiatives to improve efficiency, which may pose risks if the expected outcomes are not achieved. The adjusted net operating loss remains significant at $5.9 million.
Supply Chain Risks: While the company states that its direct exposure to tariffs is negligible, any unforeseen supply chain disruptions could impact production and sales.
Economic Factors: The company operates in a market with a high prevalence of obesity, but economic downturns or changes in healthcare policies could affect patient access to treatments.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
New Commercial Plan: Focus on key geographies with deeper penetration using a B2B2C direct sales model.
FDA Approval: Gaining FDA approval for the Allurion Balloon and preparing for U.S. launch.
Profitability Goal: Achieving profitability for the ex-U.S. business by the end of 2025.
AI Product Platform: Scaling the AI product platform and leveraging new business models.
Resuming Commercialization in France: Re-engaging clinics and re-training providers to reactivate placements.
Revenue Guidance: Maintaining guidance of revenues of approximately $3 million.
Operating Expenses Guidance: Expecting a reduction in operating expenses of approximately 50% compared to 2024.
Cash Position: Ended Q1 2025 with cash and cash equivalents of $20 million.
Future Revenue Expectations: Expect revenues to ramp as the B2B2C model expands and sales team onboards.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Cash and Cash Equivalents: As of March 31st, 2025, we had cash and cash equivalents of $20.4 million.
Operating Loss: Loss from operations for the first quarter was $7.3 million compared to $11.4 million for the same period in 2024.
Adjusted Loss from Operations: Adjusted loss from operations was $5.9 million, excluding one-time financing costs of $1.4 million.
Revenue Guidance: We are maintaining our guidance of revenues of approximately $3 million with a reduction in operating expenses of approximately 50% compared to 2024.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you give any indication in terms of what might — some of the trends that are going on regionally, whether that be Middle East or Europe, ex-France, of course, in terms of momentum, especially with the new change in marketing strategy?
A:We’re seeing regional trends following our B2B2C marketing strategy, with mature markets creating tailwinds as patients seek alternatives to GLP-1s. The expansion of our direct sales force is also contributing to new account openings and deeper engagement with existing accounts.
Q:Did you state how long you think it might take for the trial with GLP-1s? How many patients and those type of things in terms of when we can see some data from that trial?
A:Enrollment in the study is expected to begin in the latter half of this year, with a one-year follow-up for patients. The study will have at least 75 subjects across multiple sites in Europe, but the size may increase based on enrollment demand.
Q:In terms of the arms, are you considering doing an arm with the AI suite alone and with the AI suite in combination with the balloon and GLP-1s?
A:We are moving forward with a single-arm prospective trial design, using historical data for comparison, which will accelerate execution and efficiency.
Q:Is this kind of the gross margin we should anticipate for the rest of the year? Or is there further improvements?
A:We expect margins to remain in the same ballpark as the first quarter, with potential increases as revenues ramp up.
Q:Can you provide more specifics on the pre-PMA meeting and the path from here?
A:We discussed preliminary data with the FDA, and they were receptive to alternative methods for analyzing control group data, which strengthens our position.
Q:Are there any analyses to be performed around higher levels of GLP-1 use in the control arm?
A:We identified variables that could explain control group overperformance, but alternative statistical methods can correct for these, aligning with our prespecified endpoints.
Q:Are you seeing centers adopt and realizing the synergies of the Allurion program plus low or normal dosing GLP-1s already?
A:Yes, we are seeing organic adoption in the field, with physicians combining Allurion and GLP-1s, which supports our prospective trial.
Q:Can you help us think through the cadence of the improvement in sales over the next couple of quarters in 2025?
A:We expect steady revenue increases driven by onboarding new sales team members, with productivity increasing in the second half of the year.
Q:Any estimate of what you plan to spend for the prospective combo study?
A:We don’t expect the study to materially impact our budget, as we can leverage existing patient flow and clinics.
Q:Is expanded label part of the strategy for the prospective study?
A:In the short-term, it’s more about commercial implications, but long-term data could support conversations with regulators and payers.
Q:Could you talk about the procedure growth in the quarter and maybe procedure growth ex-France?
A:Procedure growth is stable globally, with some growth in certain territories. We expect to see placements in France in the second half of the year.
Q:Was the additional analysis at the FDA due to any concerns that the balloon wouldn’t be approved?
A:No, it was due to further analysis after seeing top line data, which the FDA invited and works in our favor.
Q:When do you expect the Virtual Care Suite revenues to be material?
A:We don’t expect material contributions this year or early next year, but anticipate meaningful growth as we ramp in the U.S.
Q:Review of Unclear Management Responses
A:Management avoided providing specific financial estimates for the prospective combo study and did not clarify the exact timeline for the recovery in France's revenue contribution.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Allurion product
Allurion program
Allurion vision
AllurionMeds
BBC model
Brady
Muscle
Subjects
analysis
brand name
care Allurion
clinic
combination Allurion
combination approach
dos GLP
dose escalation
dose study
effect
energy
exercise
expectation
financing reduction
level perspective
marketing period
maximum
milligram
option patient
pathway protein
patient weight
pillar plan
placement
program dose
protocol
result efficiency
semaglutide
storage
tariff
update
versatility
weight muscle
weight reduction
ALUR Transcript
Allurion Technologies Inc. (ALUR) Q3 2025 Earnings Call Transcript
Unknown11-12
The company's earnings call reveals several negative factors: a significant revenue decline, restructuring costs, and an operating loss. While there are some positive aspects, like narrowed losses and cost reductions, the overall financial health remains weak. The Q&A section highlights uncertainties in international strategy and product development timelines. Despite optimistic guidance, the combination of competitive pressures, supply chain inefficiencies, and reliance on private financing suggests a likely negative stock price reaction over the next two weeks.
Allurion Technologies Inc. (ALUR) Q2 2025 Earnings Call Transcript
Unknown8-13
The earnings call reveals a significant revenue decline, despite cost reductions. The Q&A highlights uncertainties in distributor retention and U.S. commercialization, with management providing vague responses. Additionally, the FDA approval timeline remains uncertain, and the competitive landscape is challenging. While there's potential in the combination therapy, the lack of clear guidance and ongoing strategic shifts suggest a cautious outlook, leading to a negative sentiment.
Allurion Technologies Inc. (NYSE:ALUR) Q1 2025 Earnings Call Transcript
Unknown5-15
The earnings call highlights a mixed picture. While there are positive developments like reduced operating expenses, restructuring benefits, and FDA approval progress, uncertainties remain. The Q&A reveals cautious optimism about regional growth and trial prospects but lacks concrete timelines for France's recovery. The absence of material Virtual Care Suite revenues soon adds to uncertainty. Despite positive restructuring impacts, the lack of immediate revenue growth and specific guidance tempers optimism, suggesting a neutral sentiment.
Allurion Technologies Inc. (ALUR) Q1 2025 Earnings Call Transcript
Positive5-14
The earnings call presents a generally positive outlook with increased gross profit, reduced expenses, and a decrease in operational losses, indicating improved financial health. The Q&A reveals positive momentum in key regions and confidence in FDA approval. Despite some unclear responses, the focus on strategic growth and the potential for increased revenue in the latter half of the year suggest a positive stock price movement. The absence of market cap data limits precise impact prediction, but the overall sentiment leans towards a positive reaction.
ALUR Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
